Home » ASH 2016 Multiple Myeloma Gateway

ASH 2016 Multiple Myeloma Gateway

The Myeloma Beacon’s ASH 2016 Multiple Myeloma Gateway makes it easy for patients, caregivers, medical professionals, and researchers to review the multiple myeloma research presented at the 2016 annual meeting of the American Society of Hematology (ASH).

In addition, for people attending the 2016 ASH meeting in San Diego in early December, the Gateway is a useful tool for planning what presentation and poster sessions to attend.

As in previous years, the Beacon’s editors have reviewed the abstracts for the ASH meeting and have made available here at The Beacon all myeloma-related meeting abstracts. The abstracts can be searched, and they also can be listed by session and by selected topics. See the links below for more information on how to view and access the abstracts in different ways.

Also, be sure to check back regularly in the weeks and months after the ASH 2016 meeting concludes. Many researchers make their presentations from the ASH meeting available to the Beacon’s readers, and the Beacon staff will be updating abstracts with links to presentations as the additional materials are received.

Abstracts for myeloma-related research from the 2015 ASH meeting can be viewed at this link. The ASH 2013 Myeloma Gateway is available at this link.

Gateway Index

  1. Abstracts
  2. Meeting sessions
  3. Abstracts by topic

Abstracts

The ASH abstracts at The Beacon can be searched from the search box that appears above each abstract and above all lists of abstracts.  Please note that meeting abstracts will not appear in the results of searches carried out from the Beacon's general search box located in the Beacon's top menu bar.

Meeting Sessions

The table below lists the sessions at the 2016 ASH meeting that will have at least one myeloma-related presentation. The sessions are sorted by date and time.

The hyperlink included with each session name links to a list of all myeloma-related presentations during that session.  The dates (Sat-Tue) are December 3-6, respectively.  The "# of abstracts" is the number of myeloma-related presentations scheduled to be made during the session.

*The times listed for each oral session are the scheduled times of the first myeloma-related presentation during each session.

†All locations are at the San Diego Convention Center except those marked "Hyatt" (Manchester Grand Hyatt) and "Marriott" (Marriott Marquis).

Saturday

Day Time* Session
Type		 Session Name Location† # of
Abstracts
Sat 7:30a Oral Education Session (Dispenzieri; Raje; McCarthy) Hall AB 3
Sat 9:30a Oral Education Session (Weber;Stadtmauer; Benson) Hall AB 3
Sat 9:30a Oral 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Biologic Insights from Genetics Grand Hall D (Hyatt) 6
Sat 2:00p Oral 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Prognostic Factors Grand Hall D (Hyatt) 6
Sat 2:30p Oral 624. Hodgkin Lymphoma and T/NK Cell Lymphoma – Clinical Studies: Novel Therapeutics and the Integration of PET Scans in Hodgkin Lymphoma and Peripheral T-Cell Lymphomas Room 6AB 1
Sat 4:00p Oral 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Progression Grand Hall D (Hyatt) 6
Sat 4:00p Oral 653. Myeloma: Therapy, excluding Transplantation: Clinical Studies, Minimal Residual Disease, and Biomarkers Seaport Ballroom ABCD (Hyatt) 6
Sat 5:30p Poster 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster I Hall GH 2
Sat 5:30p Poster 605. Molecular Pharmacology, Drug Resistance – Lymphoid and Other Diseases: Poster I Hall GH 2
Sat 5:30p Poster 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster I Hall GH 1
Sat 5:30p Poster 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) – Results from Retrospective/Observational Studies: Poster I Hall GH 1
Sat 5:30p Poster 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I Hall GH 36
Sat 5:30p Poster 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I Hall GH 16
Sat 5:30p Poster 653. Myeloma: Therapy, excluding Transplantation: Poster I Hall GH 29
Sat 5:30p Poster 711. Cell Collection and Processing: Poster I Hall GH 2
Sat 5:30p Poster 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster I Hall GH 3
Sat 5:30p Poster 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I Hall GH 1
Sat 5:30p Poster 731. Clinical Autologous Transplantation: Results: Poster I Hall GH 8
Sat 5:30p Poster 732. Clinical Allogeneic Transplantation: Results: Poster I Hall GH 4
Sat 5:30p Poster 802. Chemical Biology and Experimental Therapeutics: Poster I Hall GH 15
Sat 5:30p Poster 902. Health Services Research – Malignant Conditions: Poster I Hall GH 15
Sat 5:30p Poster 904. Outcomes Research – Malignant Conditions: Poster I Hall GH 6

Sunday

Day Time* Session
Type		 Session Name Location† # of
Abstracts
Sun 7:30a Oral Education Session (Weber;Stadtmauer; Benson) Hall AB 3
Sun 7:30a Oral 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Therapeutic Targets in Myeloma Grand Hall D (Hyatt) 6
Sun 8:15a Oral 331. Pathophysiology of Thrombosis: Risk Factors Room 33 1
Sun 9:30a Oral Education Session (Dispenzieri; Raje; McCarthy) Hall AB 3
Sun 9:30a Oral 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Insights from Molecular Alterations and Alternate Splicing Grand Hall D (Hyatt) 6
Sun 12:00p Oral 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Immune Approaches for Myeloma Therapy Grand Hall B (Hyatt) 6
Sun 12:00p Oral 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Clinical Insights from Multiple Myeloma Biology and Biomarkers Grand Hall D (Hyatt) 6
Sun 12:15p Oral 904. Outcomes Research – Malignant Conditions: Treatment Characteristics and Outcomes Room 30 1
Sun 4:30p Oral 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Microenvironment Room 24 6
Sun 4:30p Oral 653. Myeloma: Therapy, excluding Transplantation: New Agents for Multiple Myeloma Hall AB 6
Sun 5:00p Oral 904. Outcomes Research – Malignant Conditions: Symptoms, Toxicities, and Patient Reported Outcomes Room 29 3
Sun 5:45p Oral 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation Seaport Ballroom DE (Hyatt) 1
Sun 5:45p Oral 903. Outcomes Research – Non-Malignant Conditions: Hemostasis and Thrombosis Grand Hall B (Hyatt) 1
Sun 6:00p Poster 332. Antithrombotic Therapy: Poster II Hall GH 1
Sun 6:00p Poster 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster II Hall GH 1
Sun 6:00p Poster 605. Molecular Pharmacology, Drug Resistance – Lymphoid and Other Diseases: Poster II Hall GH 1
Sun 6:00p Poster 621. Lymphoma – Genetic/Epigenetic Biology: Poster II Hall GH 1
Sun 6:00p Poster 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II Hall GH 34
Sun 6:00p Poster 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II Hall GH 17
Sun 6:00p Poster 653. Myeloma: Therapy, excluding Transplantation: Poster II Hall GH 33
Sun 6:00p Poster 711. Cell Collection and Processing: Poster II Hall GH 3
Sun 6:00p Poster 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster II Hall GH 1
Sun 6:00p Poster 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster II Hall GH 2
Sun 6:00p Poster 731. Clinical Autologous Transplantation: Results: Poster II Hall GH 11
Sun 6:00p Poster 732. Clinical Allogeneic Transplantation: Results: Poster II Hall GH 2
Sun 6:00p Poster 802. Chemical Biology and Experimental Therapeutics: Poster II Hall GH 1
Sun 6:00p Poster 902. Health Services Research – Malignant Conditions: Poster II Hall GH 9
Sun 6:00p Poster 904. Outcomes Research – Malignant Conditions: Poster II Hall GH 4

Monday

Day Time* Session
Type		 Session Name Location† # of
Abstracts
Mon 7:00a Oral 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma I Seaport Ballroom DE (Hyatt) 6
Mon 7:15a Oral 902. Health Services Research – Malignant Conditions: Innovations in Detection, Management, and Outcomes Pacific Ballroom 21-22 (Marriott) 2
Mon 7:15a Oral 711. Cell Collection and Processing: Graft Mobilization, Manipulation, and Characterization  Seaport Ballroom BC (Hyatt) 1
Mon 10:30a Oral 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Genetic Alterations/Profiling and Clonal Evolution of Multiple Myeloma Grand Hall D (Hyatt) 6
Mon 10:45a Oral 703. Adoptive Immunotherapy II Ballroom 20A 1
Mon 11:00a Oral 902. Health Services Research – Malignant Conditions: Racial and Ethnic Disparities in Outcomes Grand Hall B (Hyatt) 3
Mon 11:30a Oral 732. Clinical Allogeneic Transplantation: Results: Reducing Relapse Seaport Ballroom DE (Hyatt) 1
Mon 2:45p Oral 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma II Seaport Ballroom DE (Hyatt) 5
Mon 2:45p Oral 653. Myeloma: Therapy, excluding Transplantation: Novel Approaches Seaport Ballroom BC (Hyatt) 6
Mon 4:30p Oral 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Targeting Tumor Microenvironment and Drug Resistance in Myeloma Grand Hall D (Hyatt) 6
Mon 4:30p Oral 653. Myeloma: Therapy, excluding Transplantation: Immunotherapy Hall AB 6
Mon 4:30p Oral 653. Myeloma: Therapy, excluding Transplantation: IMiD / Proteasome Inhibitor Combinations and Maintenance Therapy Seaport Ballroom BC (Hyatt) 6
Mon 4:45p Oral 904. Outcomes Research – Malignant Conditions: Disparities in Outcomes Room 29 4
Mon 4:45p Oral 902. Health Services Research – Malignant Conditions: At the Corner of Cost and Efficacy Room 28ABCD 1
Mon 5:45p Oral 605. Molecular Pharmacology, Drug Resistance – Lymphoid and Other Diseases: Combination Strategies for Hematologic Malignancies Room 6CF 1
Mon 6:00p Poster 201. Granulocytes, Monocytes, and Macrophages: Poster III Hall GH 1
Mon 6:00p Poster 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster III Hall GH 1
Mon 6:00p Poster 605. Molecular Pharmacology, Drug Resistance – Lymphoid and Other Diseases: Poster III Hall GH 2
Mon 6:00p Poster 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III Hall GH 2
Mon 6:00p Poster 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) – Results from Prospective Clinical Trials: Poster III Hall GH 1
Mon 6:00p Poster 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster III Hall GH 47
Mon 6:00p Poster 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster III Hall GH 23
Mon 6:00p Poster 653. Myeloma: Therapy, excluding Transplantation: Poster III Hall GH 40
Mon 6:00p Poster 703. Adoptive Immunotherapy: Poster III Hall GH 3
Mon 6:00p Poster 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution Poster III Hall GH 1
Mon 6:00p Poster 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III Hall GH 4
Mon 6:00p Poster 731. Clinical Autologous Transplantation: Results: Poster III Hall GH 14
Mon 6:00p Poster 732. Clinical Allogeneic Transplantation: Results: Poster III Hall GH 1
Mon 6:00p Poster 802. Chemical Biology and Experimental Therapeutics: Poster III Hall GH 1
Mon 6:00p Poster 901. Health Services Research – Non-Malignant Conditions: Poster III Hall GH 1
Mon 6:00p Poster 904. Outcomes Research – Malignant Conditions: Poster III Hall GH 6
Mon 6:30p Oral 902. Health Services Research – Malignant Conditions: Outcomes From a Patient's Perspective Room 28ABCD 2
Mon 7:30p Oral 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Alternative Donors Room 31 1

Tuesday

Day Time* Session
Type		 Session Name Location† # of
Abstracts
Tue 7:30a Oral Late-Breaking Abstracts Session Hall AB 1

Abstracts By Topic

The Beacon editorial team has "tagged" many of the ASH abstracts to make it easy to view abstracts about specific myeloma-related topics. The following is a list of some of the popular categories defined by the tags (or combinations of the tags).

(Please note that the tagging of the abstracts is still ongoing. It is about 75 percent complete as of Saturday, December 3, 2016.)

General Topic Specific Topics
Potential new therapies New treatments under development
Clinical trial results for new treatments
Preclinical research about new treatments
Therapies already being marketed Revlimid (lenalidomide)
Velcade (bortezomib)
Kyprolis (carfilzomib)
Pomalyst (pomalidomide, Imnovid)
Thalidomide (Thalomid)
Ninlaro (ixazomib)
Darzalex (daratumumab)
Empliciti (elotuzumab)
Cyclophosphamide (Cytoxan)
Melphalan (Alkeran)
Prednisone
Treanda (bendamustine)
Classes of therapies
(includes abstracts about single agents in the specified classes and abstracts about the class as a whole)		 Immunomodulatory agents
Proteasome inhibitors
HDAC inhibitors
Monoclonal antibodies
CAR T-cell therapies
Transplantation Transplantation (any type)
Autologous (own stem cell) transplantation
Allogeneic (donor stem cell) transplantation
Stem cell mobilization
Other therapy-related topics Maintenance therapy
Consolidation therapy
Bisphosphonate treatment
Related conditions and disease characteristics Smoldering myeloma
MGUS (monoclonal gammopathy of undetermined significance)
Plasma cell leukemia
Other topics Chromosomal abnormalities
Minimal residual disease
Gene expression profiling
Treatment biomarkers
Prognosis & survival
Multiple myeloma disease biology